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Letter to the Editor
Immunoglobulin  levels,  cytology  and  microbiologic
investigations of  broncho-alveolar  lavage  in children  with
cystic ﬁbrosisDear Editor,
Bronchoalveolar lavage (BAL) allows cells, pathogens and sol-
uble components from the distal parts of respiratory tract
to  be examined. Herein we report our data from 36 children
with  cystic ﬁbrosis (CF), aged 4–17 years, who underwent a
ﬁbrobronchoscopy with BAL aspiration. As a control group we
examined BAL ﬂuid (BALF) obtained from non-CF children. We
used the modiﬁed Chrispin–Norman chest radiograph scoring
system  (CNS) to stage disease severity.1
BAL was  performed with 10–15 mL  warm physiological
serum, 50–70% of which represents BALF. Tests were done
using  monospeciﬁc anti-A, anti-G, anti-M and anti-SC serum,
light  microscopy (for cytomorphological examination), and
elective  nutrient agars, cultures for viruses and immunoﬂuo-
rescence.
There were  no anatomical abnormalities observed. Posi-
tive  bacterial growth was  obtained in 30 patients; organisms
identiﬁed included Pseudomonas aeruginosa (n = 21) and Staphy-
lococcus  aureus (n = 12). Viruses were  not detected either
by  immunoﬂuorescence or culture. Early determination of
inﬂammation in children with CF is crucial, as persistent bac-
terial  infection leads to lung damage, long before objective
drop  of spirometric parameters. Patients with P. aeruginosa had
higher  scores in CNS (r = 0.62, p < 0.05). There was  no correla-
tion  between IgG levels and presence of P. aeruginosa (r = 0.16,
p  > 0.05); however, a correlation was  found between IgG lev-
els  and detection of S. aureus (r = 0.43, p < 0.05). Every pathogen
isolated  in these patients should be treated aggressively, for
ceasing  the vicious cycle (inﬂammation ↔ infection).2
Morphological changes of the epithelial cells were more
obvious in patients with more  severe clinical course of the
disease  (higher CNS). Large number of neutrophil leucocytes
were  detected in the cytogram, most of them showing degen-
erative  features, deformed epithelial cells, some of them with
methaplasia  and high percentage of polymorph nuclear leu-
cocytes  (PML) – over  50%. With disease progression there is an
increase  of neutrophils, and this could be used in the follow upand response to therapy. However, in cases with neutrophils
>80%,  other inﬂammatory markers should be used.3 PML  in
patients  with CF are signiﬁcantly more  elevated. There was  a
positive correlation between CNS and number of PML  (r = 0.45,
p  < 0.05).
Neutrophils in airways release high amounts of elastase
overwhelming the local antiprotease shield. Thus, the very
low  level of 1-antitrypsin (AAT) observed in all CF chil-
dren  was  not surprising. These data support the rationale
for  clinical trials with inhalation of AAT aiming at restor-
ing  the protease–antiprotease balance and attenuate airway
inﬂammation.4 We  found a weak linear correlation between
the  CNS and low level AAT (r = 0.32, p < 0.05), and a good
correlation between low levels of AAT and SIgA (r = 0.547,
p  < 0.05).
The immunoglobulin (Ig) levels, mainly SIgA, in bronchial
secretion are considered to reﬂect the state of local immunity.5
Ig levels in BALF in patients were  determined by the
type  of endobronchial changes. IgG was  the predominant
immunoglobulin, followed by IgA and IgM. IgM levels were
found  only in 27 patients, all of them with severe diffuse
purulent endobronchitis (PE). In these patients the SIgA lev-
els  in BALF were  almost zero. Average blood IgM level in
all  patients was 165 ± 72.63 mg%. SIgA levels were  highest in
cases  with catarrhal inﬂammation and signiﬁcantly lower in
PE. There was  a correlation between SIgA levels and CNS
(r  = 0.47, p < 0.05). IgG levels were higher in patients with PE
–  1567 ± 203.35 mg/dL. For the purpose of guiding treatment
BAL  was  repeated in 21 children. Indication for a repeated BAL
was  the presence of diffuse PE. We  can note, that as the clini-
cal  state of the child improves SIgA in BALF increases and IgG
decreases.
Ig  levels and cytological characteristic of BALF have signif-
icant  clinical importance in estimating the state of bronchial
mucosa, local immunity, and efﬁcacy of the treatment. Our
results  demonstrate that BALF examination is helpful in the
diagnosis  and management of chronic lung disease in chil-
dren.  BAL appeared to be a safe procedure because none of the
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xamined patients experienced any clinically relevant side-
ffects  during and after the procedure.
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